Cargando…

Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy

Epigenetics is dynamic and heritable modifications to the genome that occur independently of DNA sequence. It requires interactions cohesively with various enzymes and other molecular components. Aberrant epigenetic alterations can lead to inappropriate onset of genetic expressions and promote tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Yuanjun, Chan, Yau-Tuen, Tan, Hor-Yue, Li, Sha, Wang, Ning, Feng, Yibin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184703/
https://www.ncbi.nlm.nih.gov/pubmed/32340605
http://dx.doi.org/10.1186/s12943-020-01197-3
_version_ 1783526635816878080
author Lu, Yuanjun
Chan, Yau-Tuen
Tan, Hor-Yue
Li, Sha
Wang, Ning
Feng, Yibin
author_facet Lu, Yuanjun
Chan, Yau-Tuen
Tan, Hor-Yue
Li, Sha
Wang, Ning
Feng, Yibin
author_sort Lu, Yuanjun
collection PubMed
description Epigenetics is dynamic and heritable modifications to the genome that occur independently of DNA sequence. It requires interactions cohesively with various enzymes and other molecular components. Aberrant epigenetic alterations can lead to inappropriate onset of genetic expressions and promote tumorigenesis. As the epigenetic modifiers are susceptible to extrinsic factors and reversible, they are becoming promising targets in multiple cancer therapies. Recently, various epi-drugs have been developed and implicated in clinical use. The use of epi-drugs alone, or in combination with chemotherapy or immunotherapy, has shown compelling outcomes, including augmentation of anti-tumoral effects, overcoming drug resistance, and activation of host immune response.
format Online
Article
Text
id pubmed-7184703
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-71847032020-04-30 Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy Lu, Yuanjun Chan, Yau-Tuen Tan, Hor-Yue Li, Sha Wang, Ning Feng, Yibin Mol Cancer Review Epigenetics is dynamic and heritable modifications to the genome that occur independently of DNA sequence. It requires interactions cohesively with various enzymes and other molecular components. Aberrant epigenetic alterations can lead to inappropriate onset of genetic expressions and promote tumorigenesis. As the epigenetic modifiers are susceptible to extrinsic factors and reversible, they are becoming promising targets in multiple cancer therapies. Recently, various epi-drugs have been developed and implicated in clinical use. The use of epi-drugs alone, or in combination with chemotherapy or immunotherapy, has shown compelling outcomes, including augmentation of anti-tumoral effects, overcoming drug resistance, and activation of host immune response. BioMed Central 2020-04-27 /pmc/articles/PMC7184703/ /pubmed/32340605 http://dx.doi.org/10.1186/s12943-020-01197-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Lu, Yuanjun
Chan, Yau-Tuen
Tan, Hor-Yue
Li, Sha
Wang, Ning
Feng, Yibin
Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy
title Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy
title_full Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy
title_fullStr Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy
title_full_unstemmed Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy
title_short Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy
title_sort epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184703/
https://www.ncbi.nlm.nih.gov/pubmed/32340605
http://dx.doi.org/10.1186/s12943-020-01197-3
work_keys_str_mv AT luyuanjun epigeneticregulationinhumancancerthepotentialroleofepidrugincancertherapy
AT chanyautuen epigeneticregulationinhumancancerthepotentialroleofepidrugincancertherapy
AT tanhoryue epigeneticregulationinhumancancerthepotentialroleofepidrugincancertherapy
AT lisha epigeneticregulationinhumancancerthepotentialroleofepidrugincancertherapy
AT wangning epigeneticregulationinhumancancerthepotentialroleofepidrugincancertherapy
AT fengyibin epigeneticregulationinhumancancerthepotentialroleofepidrugincancertherapy